Pneumococcal conjugate second or third-dose vaccines (PCVc) in Poland
Poland: Pneumococcal conjugate second or third-dose vaccines (PCVc) was 89.0% in 2025. ◆ Volatile
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Poland, 2008–2025
Source: World Health Organization, Global Health Observatory.
Analysis
Poland recorded 89.0% for pneumococcal conjugate second or third-dose vaccines (pcvc) in 2025. That is the highest value across all 18 years on record.
Compared with earlier readings it is up 1.1% over five years.
Over the whole period, pneumococcal conjugate second or third-dose vaccines (pcvc) in Poland peaked at 89.0% in 2019 and was at its lowest, 0.0%, in 2008.
That places Poland 72nd out of 194 countries with data for 2025, putting it in the middle of the range.
The series is highly variable year to year, so single readings are best treated with caution.
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Poland, year by year
| Year | Value | Change |
|---|---|---|
| 2008 | 0.0% | — |
| 2009 | 0.0% | — |
| 2010 | 0.0% | — |
| 2011 | 0.0% | — |
| 2012 | 0.0% | — |
| 2013 | 0.0% | — |
| 2014 | 0.0% | — |
| 2015 | 0.0% | — |
| 2016 | 0.0% | — |
| 2017 | 0.0% | — |
| 2018 | 60.0% | — |
| 2019 | 89.0% | +48.3% |
| 2020 | 88.0% | -1.1% |
| 2021 | 88.0% | +0.0% |
| 2022 | 88.0% | +0.0% |
| 2023 | 89.0% | +1.1% |
| 2024 | 89.0% | +0.0% |
| 2025 | 89.0% | +0.0% |
Poland compared with similar countries
- Poland's 89.0% is below the median for high income countries, which is 91.0%, 98% of the median. (63 countries reporting)
- Poland's 89.0% is above the median for Europe & Central Asia, which is 87.0%, 1.0× the median. (51 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | 2 |
| 2010s | 14.9% | 0.0% | 89.0% | 10 |
| 2020s | 88.5% | 88.0% | 89.0% | 6 |
Countries ranked near Poland
More health data for Poland
- Un projection of annual infant deaths, annual growth rate -1.23 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate -0.9071 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,693 deaths per 1,000 people (2090)
- Number of infants who die before age 1 80 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 0 (2025)
- Population ages 00-04, female, annual growth rate -5.59 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0201 units per person (2025)
- Population ages 00-04, male, annual growth rate -5.49 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is pneumococcal conjugate second or third-dose vaccines (pcvc) in Poland?
- Pneumococcal conjugate second or third-dose vaccines (pcvc) in Poland was 89.0% in 2025, according to World Health Organization, Global Health Observatory.
- What is the highest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Poland?
- The highest recorded value was 89.0% in 2019.
- What is the lowest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Poland?
- The lowest recorded value was 0.0% in 2008.
- How does Poland rank for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Poland ranks 72nd out of 194 countries with data for 2025.
- Where does this Poland data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 18 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).